Biospecimen collection is one of the most operationally demanding aspects of oncology clinical trials — and one of the most consequential for data quality. Unlike eCRF data entries, which can often be corrected with a query and a signature, a rejected biospecimen cannot be recollected. A missed PBMC isolation window, a temperature excursion during shipping, or a mislabelled tube represents a permanent gap in the dataset that affects biomarker endpoints, endpoint analyses, and potentially patient safety monitoring.
For clinical trial coordinators and CRAs, biospecimen handling requires understanding a chain that runs from phlebotomy to central lab receipt — with no single weak link tolerable. This article covers that chain in full: specimen types, collection requirements, processing procedures, storage specifications, chain of custody documentation, and shipping requirements under IATA P650.
Specimen Types in Oncology Trials and Why They Matter
Oncology trials collect a wider variety of biospecimens than most other therapeutic areas, reflecting the complex biological questions being studied. Understanding what each specimen type is used for helps coordinators prioritise handling and anticipate the sensitivity of processing errors.
Peripheral Blood Mononuclear Cells (PBMCs)
Lymphocytes and monocytes isolated from whole blood via density-gradient centrifugation. Used for immunological endpoint assays (T-cell function, cytokine profiling, immune cell phenotyping). Highly time-sensitive: viability declines sharply if processing is delayed beyond protocol-specified windows.
Serum
Plasma with clotting factors removed, obtained after allowing whole blood to clot and centrifuging. Used for biomarker panels, protein assays, antibody titres, and PK/PD sampling. Collection in serum separator tubes (SST/gold-top). Haemolysis from difficult draw or rough handling is a leading rejection cause.
Plasma
The acellular component of anticoagulated blood, separated by centrifugation. Used for ctDNA liquid biopsy, cytokine analysis, and pharmacokinetic assays. Tube type is critical — different anticoagulants (EDTA, heparin, ACD-B, Streck cell-free DNA tubes) are specified for different assays and cannot be substituted.
Tumour Tissue
Fresh frozen or FFPE tissue from biopsy or resection. Used for molecular profiling, biomarker confirmation, and pharmacodynamic endpoints. Collection typically coordinated with pathology. Fixation timing for FFPE (6–72 hours in formalin) is tightly specified; early snap-freezing for fresh tissue requires -80°C or LN2 access in the procedure suite.
Urine
Mid-stream clean-catch or catheterised sample. Used for urinary biomarker panels, nephrotoxicity monitoring, and metabolomics. First-morning void often specified. Protease inhibitors may need to be added per the laboratory manual. Typically more forgiving on timing than blood-derived specimens.
Stool / Microbiome
Increasingly collected in immuno-oncology trials to correlate gut microbiome composition with treatment response. Specific collection kits with preservatives required. Temperature and time sensitivity varies by assay platform — review the lab manual carefully for each protocol that includes microbiome endpoints.
Collection Requirements and Common Errors
Most biospecimen deviations originate at the collection stage — before processing has even begun. The most preventable errors occur when coordinators are not fully familiar with the protocol's laboratory manual requirements for each visit and specimen type.
Tube Type Errors
The anticoagulant in a blood collection tube is not interchangeable. Heparin inhibits PCR-based assays and cannot be used where DNA amplification is required. EDTA chelates calcium, affecting some coagulation and calcium-sensitive assays. Streck cell-free DNA BCT tubes preserve circulating tumour DNA integrity that standard EDTA tubes do not. Using the wrong tube type is an irreversible deviation — the sample cannot be corrected retroactively.
Collection Timing
Many oncology trial biospecimen collections are time-specific — relative to drug administration, a meal, a prior procedure, or time of day. Pre-dose blood draws must occur before any study drug is administered; post-dose PK draws must occur within defined windows (often ±5 or ±10 minutes). Visits that compress the schedule to accommodate patient or clinic convenience — collecting pre-dose and post-dose samples outside the protocol window — generate deviations that affect PK analyses. Coordinators should print the lab visit schedule for each patient visit and verify timing with the clinical team before the patient arrives.
Volume Requirements
Insufficient blood volume is among the most common causes of sample rejection. Each tube type has a minimum fill volume for the assay to function correctly; many protocols also specify a maximum fill volume to avoid dilution effects. The laboratory manual should list volume requirements per tube type per visit. Total collection volumes must also be summed against any protocol-specified blood volume limits per visit and per study period — a consideration particularly important in paediatric oncology studies.
PBMC Isolation: Procedure and Timing Requirements
PBMC isolation is among the most time-critical and technique-sensitive procedures in oncology trial biospecimen processing. An error in isolation technique or a delay beyond the protocol window can render a sample unusable for immunological assays even if the collection itself was perfect.
Standard Isolation Procedure (Ficoll Density Gradient)
Invert the collection tube 8–10 times immediately after collection to mix anticoagulant. Do not vortex. Transport upright at ambient temperature (18–25°C) to the processing laboratory. Do not refrigerate or place on ice — cold temperatures cause platelet clumping that contaminates the mononuclear cell layer.
Dilute whole blood 1:1 with PBS or Hank's balanced salt solution in a conical tube. This reduces viscosity and improves the sharpness of the density gradient interface. The ratio may be specified differently in some protocols — follow the laboratory manual exactly.
Carefully layer the diluted blood over Ficoll-Paque reagent in a 50 mL conical tube at approximately 1:1 ratio. This must be done gently — disturbing the interface before centrifugation disrupts the gradient. Some protocols specify SepMate or Leucosep tube inserts to simplify this step.
Centrifuge at 400–500 × g for 30–35 minutes at room temperature with the brake off or at low setting. The buffy coat layer (PBMCs) forms at the Ficoll-blood interface; red blood cells and granulocytes pellet through the Ficoll. Centrifuge brake settings are often specified — high brake disrupts the interface.
Using a sterile pipette, aspirate the buffy coat layer into a fresh conical tube. Wash twice with PBS (centrifuge at 300 × g for 10 minutes) to remove Ficoll residue and platelets. After the final wash, resuspend in the cryopreservation medium specified by the laboratory manual.
Count cells using a haemocytometer and trypan blue exclusion, or an automated cell counter. Record cell count and viability percentage on the laboratory worksheet. Most protocols specify a minimum viability threshold (commonly ≥80%) for sample acceptability. Record results and indicate pass/fail on the chain-of-custody form.
Transfer to cryovials at the protocol-specified concentration in freezing medium (commonly 90% FBS + 10% DMSO, or a proprietary medium). Place in a controlled-rate freezing container (e.g., Mr. Frosty) pre-equilibrated at room temperature and transfer immediately to -80°C. Leave for 24 hours before transferring to long-term liquid nitrogen vapour storage if specified.
Storage Requirements: -80°C and Liquid Nitrogen
Most oncology trial biospecimens intended for shipment to a central lab are stored at -80°C (±10°C) from the point of processing until shipment. Some protocols specify liquid nitrogen vapour-phase storage (approximately -135°C to -190°C) for archival samples or samples where long-term stability is critical.
Ultra-Low Temperature Freezer Requirements
- Continuous temperature monitoring with a calibrated data logger; sponsor-required documentation of continuous temperature records, not just twice-daily manual checks
- High-low alarm system that triggers at the protocol-specified excursion thresholds (typically -60°C and -100°C for a -80°C freezer), with escalation to staff 24/7
- Backup power provision documented in the site's emergency plan; UPS or generator connection for -80°C freezers holding protocol samples
- Annual calibration of temperature monitoring equipment; calibration certificate in the site file
- Dedicated location for clinical trial samples — separated from non-trial samples and clearly labelled with study-specific identifiers
Temperature Excursion Handling
If a temperature excursion occurs — freezer alarm triggers, power failure, or samples inadvertently stored at incorrect temperature — the site must document the excursion immediately, notify the sponsor/CRO, and quarantine the affected samples pending sponsor guidance on whether they remain evaluable. Do not discard samples or assume they are compromised without sponsor direction — some assays are more sensitive to temperature excursion than others and the sponsor's central lab will often make the acceptability determination.
Cold Chain and Shipping Under IATA P650
Clinical trial biospecimen shipments are biological specimens transported for diagnostic or investigational purposes. They are regulated as Category B biological substances under IATA Dangerous Goods Regulations, governed by IATA Packing Instruction P650, and must bear UN3373 classification labelling. Non-compliance with these regulations can result in shipment interception, sample loss, and site-level regulatory findings.
IATA P650 Packaging Requirements
| Layer | Requirement | Purpose |
|---|---|---|
| Primary container | Leak-proof cryovial or sealed tube containing the specimen; must be labelled with patient ID, study ID, visit, timepoint, and specimen type | Contains the biological material; must not leak under transport conditions |
| Absorbent material | Sufficient absorbent material to absorb the entire contents of the primary container in event of breakage | Prevents release of biological material if primary container fails |
| Secondary container | Watertight rigid or semi-rigid container surrounding the primary container and absorbent material; sealed securely | Additional containment and structural protection |
| Outer packaging | Rigid outer box sufficient to protect contents; must bear UN3373 diamond label, biohazard symbol, shipper/consignee information, and "Biological Substance, Category B" designation | External identification and regulatory compliance |
| Temperature maintenance | Dry ice (for -80°C samples) or cold packs (for 2–8°C samples) per sponsor laboratory manual specifications; dry ice quantity must maintain temperature for minimum transit time plus 24-hour buffer | Maintains sample integrity throughout transport |
| Documentation inside box | Completed shipment manifest listing all enclosed samples with patient IDs, visit codes, and specimen types; completed waybill or airway bill; and the laboratory requisition form per the sponsor's system | Chain of custody traceability; central lab intake verification |
Dry Ice Handling for -80°C Samples
- Use pre-approved dry-ice shipper boxes specified by the sponsor's laboratory manual — do not substitute box sizes
- Check the estimated transit time to the central lab against the laboratory manual's required dry ice quantity; schedule shipments to arrive Monday through Thursday (avoid Friday shipments that risk weekend delays)
- Note that dry ice is subject to airline quantity restrictions; coordinate with the courier service for quantities exceeding airline limits
- Do not seal cryovials in airtight secondary containers with dry ice — CO₂ sublimation can pressurise and rupture the container. Use perforated or vented secondary containers
- Document the dry ice weight at packing on the chain-of-custody form and the waybill as required by regulations
Chain of Custody Documentation
Chain of custody is the complete documented record of a biospecimen from collection to central lab receipt. It is one of the most scrutinised areas during both monitoring visits and regulatory inspections. Every handoff — from the collector to the processor, from the processor to the shipper, from the shipper to the central lab — must be documented with date, time, and the identity of the responsible person.
Chain of Custody — Required Documentation Elements
Avoiding Central Lab Rejection: The Most Common Causes
Central labs report that a substantial proportion of oncology trial biospecimen rejections are preventable with better site-level process adherence. Understanding the leading rejection causes allows sites to implement targeted quality checks before shipment.
Temperature Excursion
Single leading cause of rejection. Samples received outside the specified temperature range — most commonly because dry ice was insufficient for the transit time, the shipper was not pre-chilled, or the shipment was delayed at a hub. Ship on Monday–Wednesday and verify courier transit times before selecting service level.
Processing Delay
Time from collection to processing exceeds the protocol-specified window. Caused by late phlebotomy, understaffed processing lab, or competing clinical demands on collection day. Schedule collection visits with processing time explicitly protected in the clinic day.
Haemolysis
Red cell lysis contaminating serum or plasma. Caused by traumatic venipuncture, excessive tube agitation, or drawing through a small-gauge IV line. Visible as pink to red discolouration in serum/plasma tubes. Some rejection threshold is specified in the laboratory manual (typically Grade 2+ haemolysis).
Insufficient Volume
Sample below minimum assay volume. Caused by difficult draw, early tube withdrawal, or tube underfilling. Verify each tube meets the minimum fill mark before releasing the patient from the chair. Some labs accept partial volume with reduced assay panel — contact the lab before shipping.
Wrong Tube Type
Incompatible anticoagulant for the specified assay. Most often occurs when a substitute tube is used because the protocol-specified tube is out of stock. Pre-order tube types specifically for each visit and maintain a site inventory tracked by the coordinator.
Missing or Incorrect Label
Patient ID, visit code, or timepoint absent, illegible, or incorrect. Labels printed from electronic systems reduce this risk vs. handwritten labels. Verify label against the patient's consent form ID and the collection schedule before the patient leaves. Never relabel a tube after collection without documented sponsor authorisation.